AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
High efficiency electroporation of human umbilical cord blood CD34(+) hematopoietic precursor cells
Authors: Wu, MH Smith, SL Dolan, ME
Citation: Mh. Wu et al., High efficiency electroporation of human umbilical cord blood CD34(+) hematopoietic precursor cells, STEM CELLS, 19(6), 2001, pp. 492-499
Efficient expression of foreign genes in human CD34(+) hematopoietic precursor cells using electroporation
Authors: Wu, MH Liebowitz, DN Smith, SL Williams, SF Dolan, ME
Citation: Mh. Wu et al., Efficient expression of foreign genes in human CD34(+) hematopoietic precursor cells using electroporation, GENE THER, 8(5), 2001, pp. 384-390
Inactivation of O-6-alkylguanine-DNA alkyltransferase by 8-substituted O-6-benzylguanine analogs in mice
Authors: Ewesuedo, RB Wilson, LR Friedman, HS Moschel, RC Dolan, ME
Citation: Rb. Ewesuedo et al., Inactivation of O-6-alkylguanine-DNA alkyltransferase by 8-substituted O-6-benzylguanine analogs in mice, CANC CHEMOT, 47(1), 2001, pp. 63-69
Optimization of culture conditions to enhance transfection of human CD34(+) cells by electroporation
Authors: Wu, MH Smith, SL Danet, GH Lin, AM Williams, SF Liebowitz, DN Dolan, ME
Citation: Mh. Wu et al., Optimization of culture conditions to enhance transfection of human CD34(+) cells by electroporation, BONE MAR TR, 27(11), 2001, pp. 1201-1209
Distribution and functional consequences of nucleotide polymorphisms in the 3 '-untranslated region of the human Sep15 gene
Authors: Hu, YJ Korotkov, KV Mehta, R Hatfield, DL Rotimi, CN Luke, A Prewitt, TE Cooper, RS Stock, W Vokes, EE Dolan, ME Gladyshev, VN Diamond, AM
Citation: Yj. Hu et al., Distribution and functional consequences of nucleotide polymorphisms in the 3 '-untranslated region of the human Sep15 gene, CANCER RES, 61(5), 2001, pp. 2307-2310
Debenzylation of O-6-benzyl-8-oxoguanine in human liver: implications for O-6-benzylguanine metabolism
Authors: Long, L Moschel, RC Dolan, ME
Citation: L. Long et al., Debenzylation of O-6-benzyl-8-oxoguanine in human liver: implications for O-6-benzylguanine metabolism, BIOCH PHARM, 61(6), 2001, pp. 721-726
Plasma and cerebrospinal fluid pharmacokinetics of O-6-benzylguanine and analogues in nonhuman primates
Authors: Long, L Berg, SL Roy, SK McCully, CL Song-Yoo, HW Moschel, RC Balis, FM Dolan, ME
Citation: L. Long et al., Plasma and cerebrospinal fluid pharmacokinetics of O-6-benzylguanine and analogues in nonhuman primates, CLIN CANC R, 6(9), 2000, pp. 3662-3669
Phase I clinical and pharmacological study of O-6-benzylguanine followed by carmustine in patients with advanced cancer
Authors: Schilsky, RL Dolan, ME Bertucci, D Ewesuedo, RB Vogelzang, NJ Mani, S Wilson, LR Ratain, MJ
Citation: Rl. Schilsky et al., Phase I clinical and pharmacological study of O-6-benzylguanine followed by carmustine in patients with advanced cancer, CLIN CANC R, 6(8), 2000, pp. 3025-3031
In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo
Authors: Chmura, SJ Dolan, ME Cha, A Mauceri, HJ Kufe, DW Weichselbaum, RR
Citation: Sj. Chmura et al., In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo, CLIN CANC R, 6(2), 2000, pp. 737-742
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (oltipraz) in patients with previously resected colon polyps and first-degree female relatives of breast cancer patients
Authors: Benson, AB Olopade, OI Ratain, MJ Rademaker, A Mobarhan, S Stucky-Marshall, L French, S Dolan, ME
Citation: Ab. Benson et al., Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (oltipraz) in patients with previously resected colon polyps and first-degree female relatives of breast cancer patients, CLIN CANC R, 6(10), 2000, pp. 3870-3877
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft
Authors: Patel, VJ Elion, GB Houghton, PJ Keir, S Pegg, AE Johnson, SP Dolan, ME Bigner, DD Friedman, HS
Citation: Vj. Patel et al., Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft, CLIN CANC R, 6(10), 2000, pp. 4154-4157
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer
Authors: Vokes, EE Kies, MS Haraf, DJ Stenson, K List, M Humerickhouse, R Dolan, ME Pelzer, H Sulzen, L Witt, ME Hsieh, YC Mittal, BB Weichselbaum, RR
Citation: Ee. Vokes et al., Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer, J CL ONCOL, 18(8), 2000, pp. 1652-1661
Phase I trial of carmustine plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
Authors: Friedman, HS Pluda, J Quinn, JA Ewesuedo, RB Long, L Friedman, AH Cokgor, I Colvin, OM Haglund, MM Ashley, DM Rich, JN Sampson, J Pegg, AE Moschel, RC McLendon, RE Provenzale, JM Stewart, ES Tourt-Uhlig, S Garcia-Turner, AM Herndon, JE Bigner, DD Dolan, ME
Citation: Hs. Friedman et al., Phase I trial of carmustine plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma, J CL ONCOL, 18(20), 2000, pp. 3522-3528
Pharmacokinetics of oral O-6-benzylguanine and evidence of interaction with oral ketoconazole in the rat
Authors: Ewesuedo, RB Dolan, ME
Citation: Rb. Ewesuedo et Me. Dolan, Pharmacokinetics of oral O-6-benzylguanine and evidence of interaction with oral ketoconazole in the rat, CANC CHEMOT, 46(2), 2000, pp. 150-155
O-6-benzylguanine-mediated enhancement of nitrosourea activity in Mer(-) central nervous system tumor xenografts - implications for clinical trials
Authors: Keir, ST Dolan, ME Pegg, AE Lawless, A Moschel, RC Bigner, DD Friedman, HS
Citation: St. Keir et al., O-6-benzylguanine-mediated enhancement of nitrosourea activity in Mer(-) central nervous system tumor xenografts - implications for clinical trials, CANC CHEMOT, 45(6), 2000, pp. 437-440
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
Authors: Humerickhouse, R Lohrbach, K Li, L Bosron, WF Dolan, ME
Citation: R. Humerickhouse et al., Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2, CANCER RES, 60(5), 2000, pp. 1189-1192
O-6-Benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma
Authors: Rhines, LD Sampath, P Dolan, ME Tyler, BM Brem, H Weingart, J
Citation: Ld. Rhines et al., O-6-Benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma, CANCER RES, 60(22), 2000, pp. 6307-6310
Effect of O-6-benzylguanine on alkylating agent-induced toxicity and mutagenicity in Chinese hamster ovary cells expressing wild-type and mutant O-6-alkylguanine-DNA alkyltransferases
Authors: Cai, YN Wu, MH Xu-Welliver, M Pegg, AE Ludeman, SM Dolan, ME
Citation: Yn. Cai et al., Effect of O-6-benzylguanine on alkylating agent-induced toxicity and mutagenicity in Chinese hamster ovary cells expressing wild-type and mutant O-6-alkylguanine-DNA alkyltransferases, CANCER RES, 60(19), 2000, pp. 5464-5469
Determination of 8-oxoguanine in human plasma and urine by high-performance liquid chromatography with electrochemical detection
Authors: Long, LN McCabe, DR Dolan, ME
Citation: Ln. Long et al., Determination of 8-oxoguanine in human plasma and urine by high-performance liquid chromatography with electrochemical detection, J CHROMAT B, 731(2), 1999, pp. 241-249
Mechanisms of resistance to the toxicity of cyclophosphamide
Authors: Gamcsik, MP Dolan, ME Andersson, BS Murray, D
Citation: Mp. Gamcsik et al., Mechanisms of resistance to the toxicity of cyclophosphamide, CUR PHARM D, 5(8), 1999, pp. 587-605
O-6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: Implications for treatment with alkylating agents
Authors: Dolan, ME McRae, BL Ferries-Rowe, E Belanich, M van Seventer, GA Guitart, J Pezen, D Kuzel, TM Yarosh, DB
Citation: Me. Dolan et al., O-6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: Implications for treatment with alkylating agents, CLIN CANC R, 5(8), 1999, pp. 2059-2064
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrentor advanced head and neck cancer
Authors: Humerickhouse, RA Dolan, ME Haraf, DJ Brockstein, B Stenson, K Kies, M Sulzen, L Ratain, MJ Vokes, EE
Citation: Ra. Humerickhouse et al., Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrentor advanced head and neck cancer, CLIN CANC R, 5(2), 1999, pp. 291-298
Lack of evidence for a polymorphism at codon 160 of human O-6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer
Authors: Wu, MH Lohrbach, KE Olopade, OI Kokkinakis, DM Friedman, HS Dolan, ME
Citation: Mh. Wu et al., Lack of evidence for a polymorphism at codon 160 of human O-6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer, CLIN CANC R, 5(1), 1999, pp. 209-213
Modulation of cyclophosphamide activity by O-6-alkylguanine-DNA alkyltransferase
Authors: Friedman, HS Pegg, AE Johnson, SP Loktionova, NA Dolan, ME Modrich, P Moschel, RC Struck, R Brent, TP Ludeman, S Bullock, N Kilborn, C Keir, S Dong, Q Bigner, DD Colvin, OM
Citation: Hs. Friedman et al., Modulation of cyclophosphamide activity by O-6-alkylguanine-DNA alkyltransferase, CANC CHEMOT, 43(1), 1999, pp. 80-85
Inhibition of O-6-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats
Authors: Wali, RK Skarosi, S Hart, J Zhang, YC Dolan, ME Moschel, RC Nguyen, L Mustafi, R Brasitus, TA Bissonnette, M
Citation: Rk. Wali et al., Inhibition of O-6-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats, CARCINOGENE, 20(12), 1999, pp. 2355-2360
Risultati: 1-25 | 26-26